BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 30885343)

  • 41. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G; Özekinci S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology.
    Louw A; Lee YCG; Acott N; Creaney J; van Vliet C; Chai SM
    Cytopathology; 2022 Jan; 33(1):84-92. PubMed ID: 34033161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion.
    Ma GY; Shi S; Wang P; Wang XG; Zhang ZG
    Biomed Rep; 2022 Aug; 17(2):66. PubMed ID: 35815188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
    Savic I; Myers J
    Acta Med Acad; 2021 Apr; 50(1):197-208. PubMed ID: 34075773
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
    Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
    Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma.
    Hamasaki M; Kinoshita Y; Yoshimura M; Matsumoto S; Kamei T; Hiroshima K; Sato A; Tsujimura T; Kawahara K; Nabeshima K
    Histopathology; 2019 Jul; 75(1):153-155. PubMed ID: 30957899
    [No Abstract]   [Full Text] [Related]  

  • 49. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
    Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years.
    Hidaka K; Takeda T; Kinoshita Y; Nabeshima K; Tamiya S; Yoshikawa Y; Tsujimura T
    Pathol Int; 2020 Dec; 70(12):1009-1014. PubMed ID: 32956524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
    Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
    Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genomic Deletion of
    Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
    Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
    Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
    Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
    [No Abstract]   [Full Text] [Related]  

  • 57. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
    Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
    Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
    Minami K; Jimbo N; Tanaka Y; Hokka D; Miyamoto Y; Itoh T; Maniwa Y
    Virchows Arch; 2020 Mar; 476(3):469-473. PubMed ID: 31667596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K
    Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.